Does TRICARE Cover Crestor (Rosuvastatin)? Coverage, Step Therapy, and Appeals Explained

What Is the TRICARE Formulary Status for Crestor?

Generic rosuvastatin is listed as a preferred generic on the TRICARE formulary, which means it is covered at the lowest copay tier with no prior authorization needed. Brand-name Crestor occupies the non-preferred brand tier and requires step therapy documentation before TRICARE will pay. The clinical rationale for preferring generics is straightforward: the FDA-approved generic contains the same active moiety at identical doses, and bioequivalence studies must show AUC and Cmax within 80 to 125 percent of the reference product to receive approval. [1]

TRICARE uses the Express Scripts Pharmacy network for retail and mail-order benefits. As of the 2024 benefit year, a 30-day supply of generic rosuvastatin at a TRICARE network retail pharmacy costs approximately $11 under TRICARE Select. [2] A 90-day supply through the Express Scripts home-delivery program costs $0 for most TRICARE Prime and Select beneficiaries, making the generic the most cost-efficient option for long-term lipid management. [2]

Brand Crestor carries a manufacturer list price near $290 per month. [3] Cash-pay programs and discount cards can bring that figure to roughly $15 per month at certain pharmacies, but those savings cards cannot be used when any federal health program, including TRICARE, is the payer. Federal anti-kickback statute regulations under 42 U.S.C. § 1320a-7b explicitly prohibit manufacturer coupons that reduce a federal beneficiary's out-of-pocket cost. [4]

The ACC/AHA 2019 guideline on the primary prevention of cardiovascular disease states: "In adults 40 to 75 years of age without diabetes mellitus and with LDL-C levels of 70 to 189 mg/dL, using a pooled cohort equations 10-year CVD risk of 7.5% or greater, it is reasonable to start a moderate- or high-intensity statin." [5] TRICARE formulary design reflects this guidance by ensuring multiple statins are accessible at low cost.

Does TRICARE Require Step Therapy Before Crestor?

Yes. Step therapy applies to brand-name Crestor at TRICARE network pharmacies. Before TRICARE will approve a claim for the brand product, the pharmacy benefit manager generally requires evidence that the beneficiary has trialed at least one preferred statin, most commonly atorvastatin 10 to 80 mg or simvastatin 10 to 40 mg. [2]

Step therapy is a standard cost-management tool across most formularies, not a denial of care. If atorvastatin brings LDL-C to goal, the clinical need for rosuvastatin specifically is absent. But rosuvastatin does have a distinct pharmacological profile. It is the most hydrophilic of the approved statins, which some evidence links to a lower rate of muscle-related adverse effects compared to more lipophilic agents such as simvastatin. [6] A prescriber can use this distinction in a prior authorization request or appeal.

The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced the composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44 percent compared to placebo (hazard ratio 0.56 to 95% CI 0.46 to 0.69, P<0.00001) in adults with elevated high-sensitivity CRP despite LDL-C below 130 mg/dL. [7] That trial enrolled individuals who specifically benefited from rosuvastatin's high-intensity LDL-lowering and anti-inflammatory properties. If your physician is prescribing Crestor based on a JUPITER-like risk profile, that rationale should appear explicitly in the PA request.

Step therapy exemptions exist for certain clinical situations under TRICARE policy. Beneficiaries with a documented history of statin-induced myopathy or rhabdomyolysis on a preferred agent may be exempted. Patients already stable on brand Crestor for six months or more at the time of enrollment in a new TRICARE plan may also qualify for a continuity-of-care exemption, though this is assessed case by case. [2]

What Are the Prior Authorization Criteria for Brand Crestor on TRICARE?

A prior authorization request for brand Crestor must address three core criteria: medical necessity, failure or intolerance of a preferred alternative, and alignment with an FDA-approved indication. [1]

Medical necessity means the prescriber must document the patient's diagnosis, typically hyperlipidemia, heterozygous familial hypercholesterolemia (HeFH), or an established atherosclerotic cardiovascular disease (ASCVD) diagnosis, along with current lipid values. TRICARE will not approve a statin PA for weight loss; rosuvastatin carries no FDA indication for that purpose, and any request framed around weight reduction will be denied. [1]

Failure or intolerance of a preferred agent requires clinical records showing the patient trialed atorvastatin or another formulary-preferred statin. Intolerance documentation should include the specific adverse effect (myalgia, elevated creatine kinase, hepatotoxicity), the duration of the trial, and the dose attempted. A trial shorter than four weeks at therapeutic dose is rarely sufficient. [6]

FDA-approved indication is non-negotiable. Rosuvastatin's FDA label covers treatment of hyperlipidemia, mixed dyslipidemia, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and slowing progression of atherosclerosis. [1] Off-label requests have essentially no path to approval under TRICARE pharmacy benefit policy.

The ACC/AHA Pooled Cohort Equations calculator, available through the American College of Cardiology, can strengthen a PA by providing a quantified 10-year ASCVD risk score. A score at or above 7.5 percent supports high-intensity statin therapy, and rosuvastatin 20 to 40 mg is one of only two statins (along with atorvastatin 40 to 80 mg) classified as high-intensity. [5] Documenting an LDL-C reduction goal that is achievable only with high-intensity therapy, and showing atorvastatin was ineffective or not tolerated, creates a defensible clinical record.

How to Appeal a TRICARE Denial of Crestor

A denial does not end the process. TRICARE has a structured multi-level appeal pathway, and the denial letter itself must state the reason for denial along with your rights. Read it carefully before writing anything. [2]

Level 1: Reconsideration Request. Submit this to the TRICARE pharmacy contractor (Humana Military for the East and West regions, International SOS for Overseas) within 90 days of the denial notice. The request should include a physician letter, updated clinical notes, lab values (fasting lipid panel, CRP if relevant), and documentation of any prior statin trial. Processing typically takes 30 days for standard requests and 72 hours for urgent clinical situations. [2]

Level 2: TRICARE Formal Appeal. If the reconsideration is denied, you may file a formal appeal to the Defense Health Agency (DHA). This must be filed within 90 days of the Level 1 denial. The DHA reviews the full clinical record and applies the same formulary exception criteria, but with a separate panel of reviewers. [2]

Level 3: External Review. Beneficiaries have the right to request an independent external review. This step invokes an independent review organization outside the TRICARE system and carries no cost to the beneficiary. External reviewers apply evidence-based clinical criteria without financial stake in the outcome, and approval rates at this level can be meaningfully higher than at internal review stages when clinical documentation is complete. [2]

Concrete tips that improve appeal outcomes: submit a peer-reviewed reference (JUPITER, published in the New England Journal of Medicine, is indexed at PubMed ID 18997196) alongside the physician letter; include a calculation showing the patient's 10-year ASCVD risk and the projected LDL-C reduction needed to reach goal; and request a peer-to-peer call between the prescribing physician and the plan's medical director, which TRICARE contractors are required to support upon request. [7]

What Does Rosuvastatin Actually Do? The Clinical Evidence

Rosuvastatin belongs to the HMG-CoA reductase inhibitor class and produces dose-dependent reductions in LDL-C. At 20 mg daily, it lowers LDL-C by approximately 48 to 52 percent from baseline. At the maximum 40 mg dose, reductions approach 55 to 63 percent. [1] No other currently available statin achieves greater LDL-C lowering at milligram-equivalent doses.

The JUPITER trial enrolled 17,802 adults with LDL-C below 130 mg/dL but elevated high-sensitivity CRP at or above 2.0 mg/L. [7] The trial was stopped early at a median follow-up of 1.9 years because interim data showed a statistically significant benefit. Rosuvastatin 20 mg reduced LDL-C by 50 percent and CRP by 37 percent versus placebo. [7] The FDA subsequently approved an expanded indication for rosuvastatin for primary prevention in this CRP-elevated subpopulation based in part on JUPITER data. [1]

The ASTEROID trial (N=349) used intravascular ultrasound to measure coronary plaque burden directly. Rosuvastatin 40 mg over 24 months produced statistically significant regression of coronary atherosclerosis, with a median change in percent atheroma volume of -0.98 percent (P<0.001 vs. baseline). [8] This was the first statin trial to demonstrate plaque regression with a prospectively specified primary endpoint using IVUS.

For patients with familial hypercholesterolemia, where LDL-C commonly exceeds 190 mg/dL, high-intensity statin therapy is the cornerstone of management. The AHA scientific statement on familial hypercholesterolemia recommends initiation of statin therapy at the time of diagnosis and notes that rosuvastatin and atorvastatin at their maximum doses are the preferred agents for achieving the 50 percent or greater LDL-C reduction target. [9]

Rosuvastatin Dosing and FDA-Approved Indications

Rosuvastatin is FDA-approved for adults and for pediatric patients age 7 and older with HeFH. [1] Standard adult starting doses are 10 to 20 mg once daily, taken at any time of day with or without food. The 40 mg dose is restricted by the FDA to patients who do not reach their LDL-C goal on 20 mg, given a modestly higher risk of myopathy at maximum dose. [1]

Dose adjustments are required for specific populations. Patients of Asian ancestry (particularly those of Chinese or Japanese descent) show higher plasma rosuvastatin concentrations due to differences in OATP1B1 hepatic uptake transporter activity; the recommended starting dose for this population is 5 mg daily. [1] Patients with severe renal impairment (CrCl <30 mL/min not on dialysis) should also start at 5 mg. [1]

Drug interactions to review before prescribing include cyclosporine (contraindicated with rosuvastatin, increases AUC approximately 7-fold), and gemfibrozil (increases rosuvastatin AUC approximately 1.9-fold, dose cap at 10 mg). [1] Antacids containing aluminum and magnesium hydroxide reduce rosuvastatin Cmax by approximately 54 percent when taken simultaneously; separate dosing by at least two hours. [1]

Comparing TRICARE Cost-Sharing Across Pharmacy Options

The cost-sharing structure under TRICARE differs by point of service, beneficiary category, and whether the drug is generic or brand. The following figures reflect 2024 TRICARE Select cost-sharing for rosuvastatin. [2]

At a TRICARE network retail pharmacy, generic rosuvastatin (30-day supply) costs approximately $11. Brand Crestor, if approved after step therapy, costs approximately $28 to $44 depending on the tier assignment at the specific pharmacy.

At the TRICARE Mail Order Pharmacy (TMOP) through Express Scripts, a 90-day supply of generic rosuvastatin costs $0 for most beneficiaries. Brand Crestor at TMOP would cost approximately $43 for a 90-day supply if authorized.

At a non-network retail pharmacy, beneficiaries pay a higher percentage of the cost. Generic rosuvastatin at a non-network pharmacy runs roughly $15 to $20 for 30 days under TRICARE Select. Using a non-network pharmacy should be a last resort for maintenance medications like statins.

TRICARE for Life (TFL) beneficiaries, those on Medicare who also have TRICARE, generally have Medicare Part D serve as primary payer and TRICARE as secondary. In that configuration, the Medicare formulary tier and copay apply first, and TRICARE covers most or all remaining cost-sharing. TFL beneficiaries should verify rosuvastatin coverage through their Medicare Part D plan rather than treating TRICARE as the primary payer. [2]

Safety Profile and Monitoring Requirements

Rosuvastatin is generally well tolerated. The most common adverse effects are myalgia (reported in approximately 3 to 5 percent of patients in clinical trials), headache, and nausea. [1] Clinically significant myopathy (defined as muscle symptoms plus CK elevation greater than 10 times the upper limit of normal) is rare, occurring in roughly 1 per 10,000 patient-years of statin use across the class. [6]

The FDA requires a baseline liver function assessment before starting rosuvastatin. Routine monitoring of liver enzymes during therapy is not recommended by current guidelines unless symptoms suggest hepatotoxicity. [1] The 2022 ACC Expert Consensus Decision Pathway on statin safety, published in the Journal of the American College of Cardiology, states that "routine monitoring of CK in asymptomatic patients on statin therapy is not recommended." [10]

New-onset diabetes risk is a class effect of statins. A meta-analysis of 13 randomized trials (N=91,140) found that statin therapy was associated with a 9 percent increase in the risk of incident diabetes (OR 1.09 to 95% CI 1.02 to 1.17). [11] This risk does not negate the cardiovascular benefit in patients at elevated ASCVD risk, but it should be discussed during shared decision-making, particularly in patients with pre-diabetes or metabolic syndrome.

Pregnancy is a contraindication. Rosuvastatin is FDA Pregnancy Category X based on animal data showing fetal harm; women of childbearing potential should use effective contraception during therapy. [1]

Is Generic Rosuvastatin the Same as Crestor?

Generic rosuvastatin contains the same active ingredient (rosuvastatin calcium) at the same labeled dose. The FDA requires all generic manufacturers to demonstrate bioequivalence to the reference listed drug, meaning the 90 percent confidence interval for the AUC ratio must fall within 80 to 125 percent. [3] For a drug with a well-characterized dose-response relationship like rosuvastatin, this standard reliably produces equivalent clinical outcomes.

Some patients raise concerns about inactive ingredients (excipients) differing between generic and brand formulations. Excipients do vary, and in rare cases a patient with a specific excipient allergy or sensitivity may have a clinical reason to prefer brand over generic. This is a legitimate argument for a PA exception, though it requires documentation of a confirmed allergy or documented adverse reaction to the generic excipient, not simply a preference. [3]

The FDA maintains a searchable Orange Book database listing all approved generic rosuvastatin products and their bioequivalence ratings. Multiple generic manufacturers hold AB ratings, meaning full therapeutic equivalence to Crestor has been confirmed. [3]